Higher 13‐Gene‐Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T‐Cell Lymphoma Patients
Advanced Biology · 2023
DOI: 10.1002/adbi.202300042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Biology, 2023. Verfasst von Cunte Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, …. Hauptthemen laut MEDLINE: Neoplasms, Lymphoma, T-Cell, Peripheral, F-Box Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Intergovernmental International Cooperation on Scientific and Technological Innovation project of Chinese Ministry of Science and Technology, Guangdong Science and Technology Project, Guangdong Medical Research Fund.
Abstract (Originalsprache)
Exome sequencing of in situ tumor samples reveals that mutated genes can predict the prognosis of patients with T‐cell lymphoma (TCL). However, how tumor mutation burden (TMB) derived from circulating tumor DNA (ctDNA) may stratify TCL patients remains unclear.The plasma ctDNA of 79 newly diagnosed TCL patients from the clinical center is used for targeted exome sequencing, and the exome data of 4035 TCL patients from the Catalogue of Somatic Mutations in Cancer (COSMIC) database is obtained for comparison analysis.TCL patients with higher TMB, as evaluated with a panel of 120 genes (panel‐TMB120), are associated with poor prognosis. More importantly, COX regression analysis identifies a subset of 13 genes in panel‐TMB120, including AP3B1 (Adaptor related protein complex 3 subunit beta 1), ATM (Ataxia‐telangiectasia mutated), BCL6 (B cell lymphoma 6), BRAF (B‐Raf proto‐oncogene, serine/threonine kinase), CDKN2B (Cyclin dependent kinase inhibitor 2B), EPCAM (Epithelial cell adhesion molecule), FBXO11 (F‐box protein 11), JAK1 (Janus kinase 1), MDM2 (Murine double minute 2), NF1 (Neurofibromin 1), STAT5B (Signal transducer and activator of transcription 5B), STAT6 (Signal transducer and activator of transcription 6), and TET2 (Tet methylcytosine dioxygenase 2), which are significantly associated with prognosis. Specifically, higher TMB values calculated with these 13 genes (panel‐TMB13) are able to significantly predict unfavorable prognosis for these patients. Together, panel‐TMB13 and the International Prognostic Index (IPI) are used for risk stratification.Panel‐TMB13 is identified, which can predict poor prognosis for TCL patients carrying higher panel‐TMB13 scores and suggest that panel‐TMB13 may be a potential biomarker for supplement risk stratification of TCL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, P. R. China.
- Department of Lymphoma, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, 510180, P. R. China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, P. R. China.
- School of Public Health, Nanjing Medical University, Nanjing, 211166, P. R. China.
- Key Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, 510632, P. R. China.
ORCID-Profile: Cunte Chen, Chengwu Zeng, Yangqiu Li
Förderung
- Intergovernmental International Cooperation on Scientific and Technological Innovation project of Chinese Ministry of Science and Technology
- Guangdong Science and Technology Project
- Guangdong Medical Research Fund
- Research Grant of Key Laboratory of Regenerative Medicine, Ministry of Education, Jinan University
- Guangdong Natural Science Foundation
- Medical Scientific Research Foundation of Guangdong Province
- Major program of Summit Project, Guangdong Province High-level Hospital Construction Project of Guangdong Provincial People's Hospital, Guangdong Academy of Me…
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Chen, C., Huang, L., Chen, Z., Ou, Q., Liu, S., Jiang, X., Chen, F., Wei, X., Guo, H., Shao, Y., Zeng, C., Li, Y., & Li, W. (2023). Higher 13‐Gene‐Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T‐Cell Lymphoma Patients. Advanced Biology. https://doi.org/10.1002/adbi.202300042
Vancouver
Chen C, Huang L, Chen Z, Ou Q, Liu S, Jiang X, et al. Higher 13‐Gene‐Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T‐Cell Lymphoma Patients. Advanced Biology. 2023. doi:10.1002/adbi.202300042
BibTeX
@article{Chen2023,
author = {Chen, Cunte and Huang, Ling and Chen, Zheng and Ou, Qiuxiang and Liu, Sichu and Jiang, Xinmiao and Chen, Feili and Wei, Xiaojuan and Guo, Hanguo and Shao, Yang and Zeng, Chengwu and Li, Yangqiu and Li, Wenyu},
title = {Higher 13‐Gene‐Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T‐Cell Lymphoma Patients},
journal = {Advanced Biology},
year = {2023},
doi = {10.1002/adbi.202300042}
}
EUVIMED